SOHO 2022 | How the IPSS-M score helps personalizing treatment & combination therapies in HR-MDS
Jacqueline Garcia
• 28 Sep 2022
Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, discusses how the newly implemented IPSS-Molecular (IPSS-M) score helps to better risk stratify patients with myelodysplastic syndromes (MDS) and helps to better select therapies for patients with specific genetic subtypes, sharing her excitement for data from clinical trials evaluating different combinatorial strategies in high-risk MDS. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
